Clinical Trial

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Patients will receive treatment for up to 8 weeks.
Trial Details
NCT Number NCT07756593
Lead Sponsor Washington University School of Medicine
Collaborators: Dendreon, ImmunityBio, Inc.
Conditions Prostate Cancer, Metastatic Prostate Cancer
Enrollment 30 participants
Start Date 2026-11-30
Primary Completion 2029-04-14 (estimated)
Study Completion 2031-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10